Pfizer Launches Inspra; Will Help Company Reach $54 Bil. In 2004
Executive Summary
Pfizer is beginning its launch of the congestive heart failure therapy Inspra
You may also be interested in...
Outcomes Data For Pfizer's Inspra Could Give Heart Failure Drug A Jumpstart
Pfizer's heart failure drug Inspra (eplerenone) has been a spectacular commercial flop since it officially launched in 2004, but the drug could have renewed potential based on the results of new outcomes data. Pfizer announced May 27 that it is halting recruitment in an outcomes trial evaluating Inspra in a broader patient population early due to positive efficacy
Outcomes Data For Pfizer's Inspra Could Give Heart Failure Drug A Jumpstart
Pfizer's heart failure drug Inspra (eplerenone) has been a spectacular commercial flop since it officially launched in 2004, but the drug could have renewed potential based on the results of new outcomes data. Pfizer announced May 27 that it is halting recruitment in an outcomes trial evaluating Inspra in a broader patient population early due to positive efficacy
Outcomes Data For Pfizer's Inspra Could Give Heart Failure Drug A Jumpstart
Pfizer's Inspra has been a commercial flop, but now a post-marketing study has shown positive results in a broader patient population